Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hypiran is an herbal pharmaceutical product developed by Poursina Pharmacy Company, formulated as oral drops containing a standardized extract of *Hypericum perforatum* (St. John's Wort). It is primarily indicated for the treatment of mild to moderate depression, anxiety, and sleep disorders. The therapeutic efficacy of Hypiran is attributed to its active constituents, such as hypericin and hyperforin, which modulate the central nervous system by inhibiting the reuptake of key neurotransmitters including serotonin, norepinephrine, and dopamine. In addition to its use in mood disorders, Hypiran is also utilized for the relief of migraine, tension headaches, and menopausal symptoms. As a standardized herbal extract, it provides a multi-target pharmacological approach to managing psychological and neurological conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hypiran.